| scholarly article | Q13442814 |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atrial fibrillation | Q815819 |
| aspirin | Q18216 | ||
| P304 | page(s) | 1273-1277 | |
| P577 | publication date | 1998-04-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators | |
| P478 | volume | 279 |
| Q35986742 | A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits |
| Q51868848 | A problem for achieving informed choice. |
| Q38185595 | AF Detected on Implanted Cardiac Implantable Electronic Devices: Is There a Threshold for Thromboembolic Risk? |
| Q37496271 | AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score |
| Q34958223 | Anticoagulants for atrial fibrillation: why is the treatment rate so low? |
| Q35142419 | Antithrombotic medication for cardioembolic stroke prevention |
| Q34362901 | Antithrombotic therapy in cardiac embolism |
| Q28165677 | Aspirin for the prevention of cardiovascular events in the elderly |
| Q36001150 | Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study |
| Q30234626 | Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes |
| Q33168630 | Atrial Fibrillation: The New Epidemic of the Ageing World |
| Q28194194 | Atrial fibrillation in the elderly: facts and management |
| Q44739497 | Barriers to the use of warfarin: potential solutions |
| Q38372615 | CHA2DS2-VASc Score: A Predictor of Thromboembolic Events and Mortality in Patients With an Implantable Monitoring Device Without Atrial Fibrillation |
| Q35660120 | CHADS(2) score is predictive of left atrial thrombus on precardioversion transesophageal echocardiography in atrial fibrillation |
| Q36679380 | CHADS2 Score is a Poor Predictor of Non-cerebral Acute Arterial Occlusion in Patients with Non-valvular Atrial Fibrillation |
| Q37159030 | Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States |
| Q37528205 | Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients |
| Q37246263 | Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies |
| Q35252790 | Coronary artery disease, left ventricular hypertrophy and diastolic dysfunction are associated with stroke in patients affected by persistent non-valvular atrial fibrillation: a case-control study |
| Q35877363 | Cost effectiveness of therapies for atrial fibrillation. A review |
| Q34048260 | Current perceptions of the epidemiology of atrial fibrillation |
| Q34746642 | Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy |
| Q38183305 | Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials |
| Q33651232 | Evidence based cardiology: Prevention of ischaemic stroke |
| Q33826206 | Guidelines for stroke prevention in patients with atrial fibrillation |
| Q49989655 | Heart failure: a weak link in CHA2 DS2 -VASc. |
| Q43097210 | How Could Pre-Procedural Imaging Guide Successful Left Atrial Appendage Closure? |
| Q33640713 | Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis |
| Q43574054 | Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study |
| Q50668031 | Ischemic Stroke Prevention. |
| Q55101940 | Just Missing the Mark: Discharging High-risk Atrial Fibrillation / Flutter without Thromboprophylaxis. |
| Q28187842 | Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation |
| Q35167436 | Management of patients with atrial fibrillation: specific considerations for the old age. |
| Q34289414 | New insights into the mechanisms and management of atrial fibrillation |
| Q37148738 | Newer anticoagulants for non-valvular atrial fibrillation |
| Q27027290 | Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q85894059 | Prediction of improvement in left atrial function index after catheter ablation for atrial fibrillation |
| Q35833389 | Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry |
| Q44701555 | Predictors of stroke risk in native Chinese with nonrheumatic atrial fibrillation: retrospective investigation of hospitalized patients |
| Q35648111 | Prevention of cardioembolic stroke |
| Q33671179 | Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin |
| Q37153566 | Risk factor management to prevent first stroke |
| Q33640707 | Risk factors for stroke and primary prevention of stroke in atrial fibrillation |
| Q28188396 | Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation |
| Q36464561 | Status of the epidemiology of atrial fibrillation |
| Q48110503 | Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores |
| Q35826197 | Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study |
| Q34027391 | Stroke prevention in atrial fibrillation |
| Q35093560 | Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants |
| Q36923167 | The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation |
| Q53421834 | The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. |
| Q85207443 | The risk stratification in atrial fibrillation |
| Q82387661 | The role of high-sensitivity C-reactive Protein, interleukin-6 and cystatin C in ischemic stroke complicating atrial fibrillation |
| Q28364499 | Toward a more practical decision analysis: a patient's perspective |
| Q34000901 | Use of oral anticoagulants in older patients |
| Q43014849 | Warfarin for non-valvar atrial fibrillation: still underused in the 21st century? |
| Q35985876 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease |
| Q37367719 | Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation |
| Q80923321 | [Anticoagulants for patients with chronic auricular fibrillation: when are they indicated?] |
Search more.